---
title: Identify candidates for gene therapy
nct_id: NCT06151002
status: RECRUITING
sponsor: University College London Hospitals
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06151002"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06151002"
last_fetched: "2026-05-10T14:07:56.445Z"
source: "Parkinson's Pathways (curated)"
---
# Identify candidates for gene therapy

**Goal (in five words):** Identify candidates for gene therapy

**Official Title:** PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's

**Trial ID:** [NCT06151002](https://clinicaltrials.gov/study/NCT06151002)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** University College London Hospitals
- **Target Enrollment:** 4800 participants
- **Start Date:** 2020-02-15
- **Completion Date:** 2025-02-14
- **Conditions:** Parkinson Disease

## Summary For Families

The team is building an online, trial-ready group of people with Parkinson's whose GBA gene status is known, so future treatments aimed at GBA-related Parkinson's can find the right participants faster. They enroll people with a formal Parkinson's diagnosis and use remote assessments plus genetic testing to determine GBA variants, keeping participants in a registry for quick referral to GBA-focused studies; this is observational, not a treatment. Adults aged 18 to 90 with Parkinson's can join, but anyone already confirmed GBA-positive will be referred to the sister RAPSODI study instead. The study excludes other types of parkinsonism, other neurological disorders, and people taking medications known to cause parkinsonism.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 90 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Formal diagnosis of Parkinson Disease

Exclusion Criteria:

* Confirmation that the individual carries a GBA variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
* History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)
* Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.
* Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
```

## Locations (1)

- University College London (UCL), London, United Kingdom _(51.5085, -0.1257)_
  - Orla Mitchell — (CONTACT) — 020 801 68413 — pdfrontline@ucl.ac.uk
  - Tony Schapira — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Orla Mitchell — (CONTACT) — 020 801 68413 — pdfrontline@ucl.ac.uk

---

*Canonical: https://parkinsonspathways.com/trial/NCT06151002*  
*HTML version: https://parkinsonspathways.com/trial/NCT06151002*  
*Source data: https://clinicaltrials.gov/study/NCT06151002*